Free Movement of Medicines and Protection of Public Health

Case C-178/20, Pharma Expressz Szolgáltató és Kereskedelmi Kft v. Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet, Judgment of the Court of Justice (Fourth Chamber) of 8 July 2021, EU:C:2021:551

In: European Journal of Health Law
Federico Forni European Commission 2055 Breydelstraat 4, 1040 Brussels Belgium

Search for other papers by Federico Forni in
Current site
Google Scholar
Download Citation Get Permissions

Access options

Get access to the full article by using one of the access options below.

Institutional Login

Log in with Open Athens, Shibboleth, or your institutional credentials

Login via Institution


Buy instant access (PDF download and unlimited online access):



In the Pharma Expressz judgment (case C-178/20) the Court of Justice clarified which conditions a Member State can impose to the import of a medicinal product not having a marketing authorisation in the national territory. The Court pointed out that a medicine not authorised in a Member State can entry in that Member State only in accordance with Article 5(1) of Directive 2001/83/EC on medicinal products for human use. Moreover, according to the Court a national measure requiring a medical prescription and a declaration from the competent national health authority is justified to protect public health although the product can be dispensed in another Member State without a medical prescription. After an overview on the development of pharmaceutical law in the EU, the contribution analyses this judgment in which the Court balanced the Treaty rules on the free movement of goods with the need to protect human health.

Content Metrics

All Time Past Year Past 30 Days
Abstract Views 301 301 20
Full Text Views 32 32 1
PDF Views & Downloads 71 71 4